PI3K/Akt/mTOR pathway is the target of SGKL based on the network pharmacology (data not shown), providing a hypothesis that it is the molecular approach linking SGKL treatment to metabolite variation in MDD. This evidence concerns the gene MTOR and major depressive disorder.